Cytisine versus nicotine for smoking cessation.

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

Placebo-controlled trials indicate that cytisine, a partial agonist that binds the nicotinic acetylcholine receptor and is used for smoking cessation, almost doubles the chances of quitting at 6 months.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

Cytisine was provided by mail, free of charge, and nicotine-replacement therapy was provided through vouchers for low-cost patches along with gum or lozenges.

How the Study Was Run

In design terms this was a randomized, open-label and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.

Everyone knew when Therapeutic nicotine (patch, non-peptide) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

The comparison arm used a placebo, so changes seen with Therapeutic nicotine (patch, non-peptide) could be set against what happens without it.

Low-intensity, telephone-delivered behavioral support was provided to both groups through the quitline.

The primary outcome was self-reported continuous abstinence at 1 month.

What Was Measured

Topics PubMed links to this paper include Alkaloids, Azocines, Nausea, Nicotine, Quinolizines, Smoking Cessation and Tobacco Use Cessation Devices.

What This Means in Plain Language

The paper is a randomized, open-label and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2014 (The New England journal of medicine), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.